Half-Year 2022 Financial and Clinical Trials Update
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A)
Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT
Indication
Solid tumors
NSCLC
Roche
Relapsed or refractory multiple myeloma (MM)
or r/r B-cell NHL
Phase/study
# of patients
Phase I
N=540
"
Phase la: Dose escalation and expansion of
tiragolumab
■ Phase Ib: Dose escalation and expansion of
tiragolumab in combination with Tecentriq
and/or other anti-cancer therapies
Phase II
CITYSCAPE
N=135
ARM A: Tecentriq plus tiragolumab
ARM B: Tecentriq monotherapy
Phase I
N=52
Phase la: Tiragolumab monotherapy
Phase Ib: Tiragolumab plus daratumumab (r/r
MM) or rituximab (r/r NHL)
"
Design
Primary endpoint
Status
CT Identifier
Safety, tolerability, PK variability and
preliminary efficacy
"
FPI Q2 2016
Data presented at AACR 2020
NCT02794571
Overall response rate and progression-free
survival
FPI Q3 2018
Recruitment completed Q2 2019
Data presented at ASCO 2020 and WCLC and
ESMO IO 2021
OBTD granted by FDA Q4 2020
Safety, tolerability, PK/PD and preliminary
efficacy
■ FPI Q2 2019
NCT03563716
NCT04045028
BTD=Breakthrough therapy designation; MM-Multiple myeloma; NSCLC=Non-small cell lung cancer; r/r-Relapsed refractory; NHL-Non-Hodgkin's lymphoma; PK-Pharmacokinetics; PD-Pharmacodynamics; ASCO=American
Society of Clinical Oncology; AACR-American Association for Cancer Research; WCLC=World Conference on Lung Cancer; ESMO IO-European Society for Medical Oncology - Immuno-Oncology
130
OncologyView entire presentation